Can a person have both asthma and chronic obstructive pulmonary disease (COPD) simultaneously?

Can You Have Both Asthma and COPD?

Yes, a person can absolutely have both asthma and COPD simultaneously—this condition is formally recognized as Asthma-COPD Overlap (ACO) and represents a distinct clinical entity affecting approximately 25% of COPD patients and 20% of asthma patients. 1, 2

Understanding Asthma-COPD Overlap

The GINA/GOLD consensus document formally recognizes this overlap syndrome and provides specific diagnostic criteria. 1 This is not simply having two separate diseases—it represents patients who demonstrate features of both conditions with important implications for prognosis and treatment.

How ACO Develops

There are multiple pathways to developing both conditions simultaneously:

• Long-standing childhood asthma can progress to incompletely reversible airflow obstruction in adults, particularly in those who smoke. 1
• Severe childhood asthma massively increases the risk for adult COPD, while only approximately 2% of children with milder asthma develop overlap. 1
• Adult smokers with childhood-onset asthma develop smaller airways throughout the entire bronchial tree compared to smokers without asthma history. 1
• Late-onset asthma (after age 40) combined with smoking exposure can lead to overlap syndrome. 3

Diagnostic Approach

When you encounter a patient with chronic airflow limitation, use the GINA/GOLD stepwise syndromic approach to identify overlap. 1

Step 1: Recognize Chronic Airways Disease

Document through clinical history, physical examination, radiology, and spirometry. 1

Step 2: Compare Features

If a patient has a similar number of asthma and COPD features (rather than three or more features clearly favoring one disease), asthma-COPD overlap is more likely. 1

Spanish Consensus Diagnostic Criteria (Most Specific)

Diagnose ACO when patients meet either: 1

• Two major criteria: FEV₁ increase ≥15% and ≥400 mL, sputum eosinophilia, and history of asthma
• One major plus two minor criteria: Major (above) plus elevated total IgE, history of atopy, and positive bronchodilator response ≥12% and ≥200 mL on two or more occasions

Japanese Respiratory Society Criteria

Look for: 1

• Paroxysmal dyspnea, cough, and wheeze worse at night and early morning
• Atopy
• Peripheral blood or sputum eosinophilia

Step 3: Confirm with Spirometry

Document post-bronchodilator FEV₁/FVC <0.7 (COPD component) along with features of airflow variability or reversibility (asthma component). 1

Critical Diagnostic Pitfall

Do not rely on bronchodilator response (BDR) alone to identify the asthma component in COPD patients. 1 BDR is not reproducible, does not relate to other typical asthma features, does not predict ICS responsiveness, and is not specific for ACO—this is "phenotype mimicry." 1

Clinical Significance and Prognosis

Patients with ACO have significantly worse outcomes than those with either disease alone: 3, 4

• Life expectancy is reduced by 9.3 years in early-onset asthma with overlap and 12.8 years in late-onset asthma with overlap compared to healthy never-smokers. 3
• Hazard ratios for hospital admissions due to exacerbations are 39.48 for early-onset ACO and 83.47 for late-onset ACO (compared to never-smokers). 3
• FEV₁ decline is accelerated to 49.6 mL/year in late-onset ACO versus 20.9 mL/year in healthy individuals. 3
• Late-onset asthma overlap (after age 40) has the worst prognosis of all phenotypes. 3

Treatment Implications

If ACO is confirmed, initiate combination ICS/LABA therapy immediately—this is the cornerstone of treatment. 1 The asthmatic component must be treated with inhaled corticosteroids regardless of COPD severity. 1

Treatment Algorithm

1. Start with ICS/LABA combination as both controller and reliever therapy. 1
2. Adjust ICS dose according to symptoms, lung function, and sputum eosinophilia. 1
3. Add LAMA (triple therapy) as disease severity increases. 1
4. Consider biological agents indicated for severe asthma in the most severe ACO patients. 2
5. Refer to specialist for complex cases requiring phenotype-specific management. 1

Treatment Caveat

Major pharmacologic trials have specifically excluded patients with both asthma and COPD, creating an "evidence-free zone" for treatment recommendations. 4 Current guidelines are based on consensus and extrapolation from single-disease trials rather than direct evidence in ACO populations. 1, 4

Key Clinical Points

• ACO is not a single disease but includes several heterogeneous phenotypes with different underlying mechanisms. 4
• Smoking cessation is critical as smoking dramatically accelerates disease progression in patients with underlying asthma. 1
• These patients require close follow-up to prevent rapid lung function decline and frequent exacerbations. 3
• Never treat ACO with SABA alone—ICS-containing medication is mandatory. 1